2,502.50
+5.04%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Caplin Point Laboratories
Its shares trade on NSE under the ticker CAPLIPOINT.NS. It has been listed since 16 November 1994. In the fiscal year to 31 March 2025, it reported revenue of ₹19.37bn and net income of ₹5.36bn. At that date it held total assets of ₹32.08bn and shareholders' equity of ₹28.50bn.
Caplin Point Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Chennai, Tamil Nadu. The firm is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). The company also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. The company has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Company’s subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 16 Nov 1994
- Employees
- 777
- Website
- caplinpoint.net ↗
Leadership
Pay as last reported
- Mr. Chingelput PaarthipanNon-Executive Chairman of the Board₹588,420
- Mr. Ashok PartheebanNon-Executive Vice Chairman of the Board
- Mr. Vivek PartheebanNon-Executive Vice Chairman of the Board, since 2011
- Mr. D. MuralidharanChief Financial Officer
- Mr. G. VenkatramCompliance Officer, General Counsel, Company Secretary
- Dr. Sridhar GanesanManaging Director, Executive Director, since 2014₹5.7m
- Mr. S. DeenadhayalanNon-Executive Independent Director₹550,000
- Mr. Komattu JohnNon-Executive Independent Director₹120,000
- Mrs. Susan MathewNon-Executive Independent Director
- Dr. R. NagendranNon-Executive Independent Director₹225,000
- Mr. Ranganathan VijayaraghavanNon-Executive Independent Director₹150,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 63
- Environment
- 22
- Social
- 92
- Governance
- 76
- Direct emissions (scope 1)
- 3,224 t
- Energy emissions (scope 2)
- 20,987 t
- Women in the workforce
- 15.37%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Caplin Point Laboratories Ltd manufactures generic pharmaceuticals and branded products for global markets.
- The company's manufacturing facility in Puducherry supports diverse product lines including injectables and ophthalmic solutions.
- Caplin Point Far East Limited and Caplin Steriles Limited enhance its global distribution capabilities.
Weaknesses
- The company employs 777 full-time employees, which may limit scalability in competitive markets.
- Caplin Point Laboratories Ltd has no presence in Asia-Pacific regions beyond Caplin Point Far East Limited.
- The company's R&D facilities are limited to Tamil Nadu, India, restricting innovation scope.
Opportunities
- Expanding into the European region offers growth potential for pharmaceutical exports.
- Latin America (LATAM) presents opportunities for increased market share in generic drugs.
- The United States of America market provides a significant opportunity for branded product sales.
Threats
- Competition in the global pharmaceutical market could impact Caplin Point's market share.
- Regulatory changes in the European region may affect product approvals and market access.
- Economic instability in Southern Africa could reduce demand for pharmaceutical products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.